Products for Research Use Only

HDAC11-IN-3

CAT: 0804-HY-173444Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-173444Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HDAC11-IN-3 (Compound A9) is a selective HDAC11 inhibitor (IC50: 4.1 nM). HDAC11-IN-3 has inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines (IC50: 10 μM). HDAC11-IN-3 has significant anti-AML activity, inducing apoptosis, cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transporters transferrin (TF) and transferrin receptor (TFRC), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which together lead to increased intracellular iron levels and induce ferroptosis in AML cells. HDAC11-IN-3 can be used alone or in combination with Cytarabine for AML research[1].
CAS Number
2989934-63-4
UNSPSC
12352005
Target
Apoptosis; Ferroptosis; HDAC; Transferrin Receptor
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Smiles
O=C(C1=C2C=C(NC2=CC=C1)C#CC3=CC=CC(C(F)(F)F)=C3)NO
Molecular Formula
C18H11F3N2O2
Molecular Weight
344.29
References & Citations
[1]Yang M, et al. HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. J Med Chem. 2025 Apr 24;68 (8) :8124-8142.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC11